C4X tapping into multi-billion dollar drug development market

MANCHESTER-based drug discovery pioneer C4X Discovery Holdings has grown its assets to £8.7m as it continues to develop treatments for addiction, chronic obstructive pulmonary disease (COPD), diabetes and multiple sclerosis.

The company, which floated on the AIM a year ago raising £11m, reported cash equivalents and deposits for the year ending July 31 of £7.5m (2014: £0.7m) in its preliminary results.

During the period the company’s anti-addiction drug Orexin progressed into formal pre-clinical and ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...